SEC Form 4 · accession 0001209191-16-156022
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Schimmel
Director
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 7:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 23, 2016 | G | 12,572 | $0.00 | D | 40,440 | D | |
| Common StockF1 | Sep 23, 2016 | G | 12,572 | $0.00 | A | 646,814 | I | See Footnote |
| Common StockF2,F1 | Dec 15, 2016 | P | 40,000 | $2.4978 | A | 686,814 | I | See Footnote |
| Common StockF1 | Dec 16, 2016 | P | 10,000 | $2.3973 | A | 696,814 | I | See Footnote |
| Common StockF3 | holding | — | — | — | 283,581 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
- F2Represents weighted price for the shares. The shares were purchased at prices ranging from $2.3469 to $2.6411 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F3These shares are owned directly by Paul R. Schimmel Prototype PSP. The Reporting Person is the trustee of the Paul R. Schimmel Prototype PSP.